Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
Itoh T, Hatano R, Horimoto Y, Yamada T, Song D, Otsuka H, Shirakawa Y, Mastuoka S, Iwao N, Aune TM, Dang NH, Kaneko Y, Okumura K, Morimoto C, Ohnuma K. Itoh T, et al. Among authors: kaneko y. Cell Death Dis. 2021 May 21;12(6):520. doi: 10.1038/s41419-021-03787-5. Cell Death Dis. 2021. PMID: 34021125 Free PMC article.
A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target.
Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, Kaneko Y, Yamada T, Dang NH, Morimoto C. Ohnuma K, et al. Among authors: kaneko y. Front Biosci (Landmark Ed). 2018 Jun 1;23(9):1754-1779. doi: 10.2741/4671. Front Biosci (Landmark Ed). 2018. PMID: 29772527 Free article. Review.
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C. Kaneko Y, et al. Biomark Res. 2021 Mar 23;9(1):21. doi: 10.1186/s40364-021-00273-0. Biomark Res. 2021. PMID: 33757558 Free PMC article.
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C. Angevin E, et al. Among authors: kaneko y. Br J Cancer. 2017 Apr 25;116(9):1126-1134. doi: 10.1038/bjc.2017.62. Epub 2017 Mar 14. Br J Cancer. 2017. PMID: 28291776 Free PMC article. Clinical Trial.
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma.
Nakagawa K, Kijima T, Okada M, Morise M, Kato M, Hirano K, Fujimoto N, Takenoyama M, Yokouchi H, Ohe Y, Hida T, Aoe K, Kishimoto T, Hirokawa M, Matsuki H, Kaneko Y, Yamada T, Morimoto C, Takeda M. Nakagawa K, et al. Among authors: kaneko y. JTO Clin Res Rep. 2021 Apr 29;2(6):100178. doi: 10.1016/j.jtocrr.2021.100178. eCollection 2021 Jun. JTO Clin Res Rep. 2021. PMID: 34590026 Free PMC article.
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
Takeda M, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T, Nosaki K, Kishimoto T, Miyashita I, Yamada M, Kaneko Y, Morimoto C, Nakagawa K. Takeda M, et al. Among authors: kaneko y. Lung Cancer. 2019 Nov;137:64-70. doi: 10.1016/j.lungcan.2019.09.010. Epub 2019 Sep 16. Lung Cancer. 2019. PMID: 31557561 Free article. Clinical Trial.
3,454 results